 Reaching consistent levels of 25OHD has been shown to be crucial in decreasing falls, fractures and increasing calcium absorption. One way to circumvent the variability of 25OHD response to vitamin D might be to use calcifediol supplementation and bypass the 25-hydroxylase enzyme entirely. This approach also permits the physician to achieve desired serum levels in a matter of just a few days, rather than the several weeks required when using native vitamin D. Compared to native vitamin D, calcifediol is more water soluble, has a shorter half-life and increases 25OHD levels more quickly. Calcifediol is also more potent, about 3.5 times more potent in raising 25OHD levels than vitamin D. Its water solubility may also confer an advantage in patients who have difficulty absorbing fat soluble vitamins. This form of vitamin D metabolite has been used historically to increase calcium absorption, treat osteomalacia, and increase Bone Mineral Density BMD. Using calcifediol seems to be a practical solution, but little is known about the dose response variability in humans and how it compares to that of native vitamin D. The investigators are intending to perform a clinical study in healthy subjects on the pharmacokinetics of different doses of Hy.D Calcifediol compared to vitamin D3 cholecalciferol in order to gain insight into the dose response relationship and to assess kinetic differences including the steady state. The metabolites 1,25OH2D, 24,25OH2D will be assessed throughout the study to assess the metabolism of vitamin D vs. 25OHD. Vitamin D3 will be measured throughout the study to assess compliance with the restriction of exogenous vitamin D supplementation. 